Payment overview · 2025
General Payments
$327.09
16 reported records · 7 companies
Healthcare provider profile · identity verified
Scott A. Asakevich, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · TULSA, OK · NPI 1356309769
Verified facts
What the public records show
CMS Open Payments records show Scott A. Asakevich, M.D. received $327.09 in general payments during 2025 across 16 reported records.
PFIZER INC. accounted for 45.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $147.37 | 45.0% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.66 | 14.6% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $38.90 | 11.9% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.99 | 7.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.95 | 7.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.26 | 7.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $20.96 | 6.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $327.09 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $147.37 | 7 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $147.37 | 7 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $38.90 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.82 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.82 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $24.99 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.95 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.26 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.26 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 44 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | 11 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
141 | 42 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
30 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 536 | 166 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 486 | 155 |
| Amlodipine Besylate | Amlodipine Besylate | 460 | 143 |
| Levothyroxine Sodium | Levothyroxine Sodium | 403 | 121 |
| Lisinopril | Lisinopril | 319 | 100 |
| Losartan Potassium | Losartan Potassium | 317 | 104 |
| Duloxetine Hcl | Duloxetine Hcl | 277 | 95 |
| Omeprazole | Omeprazole | 218 | 69 |
| Hydrochlorothiazide | Hydrochlorothiazide | 206 | 71 |
| Carvedilol | Carvedilol | 179 | 59 |
| Gabapentin | Gabapentin | 169 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 164 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 154 | 51 |
| Eliquis | Apixaban | 141 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 138 | 48 |
| Meloxicam | Meloxicam | 137 | 66 |
| Montelukast Sodium | Montelukast Sodium | 127 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 119 | 41 |
| Furosemide | Furosemide | 114 | 46 |
| Trazodone Hcl | Trazodone Hcl | 108 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 107 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 105 | 20 |
| Potassium Chloride | Potassium Chloride | 100 | 41 |
| Simvastatin | Simvastatin | 95 | 31 |
| Famotidine | Famotidine | 94 | 39 |
| Alendronate Sodium | Alendronate Sodium | 93 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 93 | 29 |
| Memantine Hcl | Memantine Hcl | 91 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 85 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 85 | 28 |
| Metformin Hcl | Metformin Hcl | 82 | 28 |
| Allopurinol | Allopurinol | 81 | 21 |
| Donepezil Hcl | Donepezil Hcl | 81 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 36 |
| Ozempic | Semaglutide | 72 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 69 | 21 |
| Spironolactone | Spironolactone | 69 | 24 |
| Farxiga | Dapagliflozin Propanediol | 66 | 18 |
| Tramadol Hcl | Tramadol Hcl | 65 | 13 |
| Baclofen | Baclofen | 60 | 29 |
| Valsartan | Valsartan | 60 | 14 |
| Sertraline Hcl | Sertraline Hcl | 59 | 21 |
| Bupropion Xl | Bupropion Hcl | 57 | 19 |
| Metformin Hcl Er | Metformin Hcl | 57 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 55 | 41 |
| Finasteride | Finasteride | 52 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 47 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | 12 |
| Jardiance | Empagliflozin | 44 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 42 | 12 |
| Trulicity | Dulaglutide | 42 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 39 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | suppressed |
| Ezetimibe | Ezetimibe | 38 | 14 |
| Glipizide Er | Glipizide | 38 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | 12 |
| Synthroid | Levothyroxine Sodium | 36 | 11 |
| Buspirone Hcl | Buspirone Hcl | 35 | 13 |
| Alprazolam | Alprazolam | 33 | 15 |
| Celecoxib | Celecoxib | 33 | suppressed |
| Methylprednisolone | Methylprednisolone | 33 | 30 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Prednisone | Prednisone | 32 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 31 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 30 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 23 |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Digoxin | Digoxin | 24 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | 11 |
| Lovastatin | Lovastatin | 23 | 11 |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 22 | 11 |
| Irbesartan | Irbesartan | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Klor-Con M20 | Potassium Chloride | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 15 |
| Mupirocin | Mupirocin | 19 | 14 |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 11 |
| Temazepam | Temazepam | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | 12 |
| Klor-Con M10 | Potassium Chloride | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Lumigan | Bimatoprost | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $327.09 · 16 records | PFIZER INC. | Dexcom G6 Transmitter, EVENITY, GEMTESA, JARDIANCE, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, UBRELVY, Veozah, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error